Every year 2000 people across Ireland are diagnosed with blood cancer, the 4th most common cause of cancer related deaths in Ireland. Of these, Myeloproliferative neoplasms (MPNs) are an important type contributing to a number of cases every year.
JAK2 V617F is widely considered to be the most clinically relevant somatic mutation in myeloproliferative neoplasms with the mutation present in 98% of polycythemia vera (PV) and 60% of Essential Thrombocythaemia (ET) and myelofibrosis (MF) cases. While wild type JAK2 acts as a signaling protein, promoting cell growth, division and survival in haematopoetic stem cells , mutated JAK2, can lead to its constitutive activation, resulting in excessive cell proliferation and contributing to myeloproliferative neoplasms (MPNs).
Early and accurate detection of the JAK2 V617F mutation is essential for the prognosis of the patient as well as informing clinicians on targeted treatment therapies including JAK inhibitors such as ruxolitinib.
That’s where the TRUPCR® JAK2 Mutation Detection Kit comes in. The TRUPCR® JAK2 Mutation Kit is based on ARMS PCR that allows for the detection of V617F mutation in JAK2 (Janus Kinase 2) gene against a background of wild-type genomic DNA.
Key Features of the TRUPCR® JAK2 Mutation Detection Testing Kit:
- The TRUPCR® JAK2 Mutation Detection Kit allows highly sensitive site-specific detection of 0.5% mutant allele in a background of 99.5% wild-type allele.
- CE-IVD
- Easy-to-use, rapid, reliable, comprehensive and cost-effective tests.
- It is compatible with various Real-time PCR instruments, including the Roche light cycler, Biorad CFX, ABI 7500 and Aria Dx.
- Complementary software analysis tool for easy detection and differentiation of mutants among wild-types.
This assay in combination with other Haemoncology markers including CALR, NPM1 and PML-RARA provides clinical labs with fast and reliable results supporting a personalized approach to treatment.
Interested in learning more, reach out today at info@medical-supply.ie
Get In Touch
